Amended Current Report Filing (8-k/a)
June 14 2021 - 6:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 3, 2021
SELLAS Life Sciences Group, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-33958
|
|
20-8099512
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
7 Times Square, Suite 2503
New York, NY 10036
|
|
|
|
|
(Address of Principal Executive
Offices) (Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (646) 200-5278
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value per share
|
SLS
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
On June 4, 2021, SELLAS Life Sciences Group, Inc. (“SELLAS”)
filed a Current Report on Form 8-K (the “Prior 8-K”) to report the transcript
of its June 3, 2021 shareholder update call. SELLAS is filing this amendment to the Prior 8-K in order to correct certain
typographical errors in the transcript, including to correct the number of patients evaluated in SELLAS’ Phase 2 Study of GPS combined
with Keytruda and to correct the number of outstanding shares of SELLAS’ common stock. The corrected transcript is filed herewith
as Exhibit 99.1. The Prior 8-K otherwise remains unchanged.
On June 3, 2021, SELLAS
Life Sciences Group, Inc. conducted a shareholder update call. A copy of the transcript of the shareholder update call is attached
as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SELLAS Life Sciences Group, Inc.
|
|
|
|
Date:June 14, 2021
|
By:
|
|
/s/ Barbara A. Wood
|
|
|
Name:
|
Barbara A. Wood
|
|
|
Title:
|
Executive Vice President, General Counsel and Corporate Secretary
|
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024